Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00285584 · ClinicalTrials.gov registry record · Phase 1
Bupropion For Reducing High-Risk Behaviors in Depressed Men Who Have Sex With Men (MSM)
A Phase 1 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT00285584 is a Phase 1 study that has completed, run by NYU Langone Health. The registered enrollment target is 41 participants.
The verdict
NCT00285584, a Phase 1 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
The primary purpose of this study was to test the whether high-risk, HIV-seronegative persons with mild-to-moderate depression would be more likely to adopt protective behavior change when provided with pharmacotherapy for their depression than when treated with placebo. High-risk behaviors include using illegal drugs and participating in unprotected sexual intercourse. The specific pharmacotherapy used in this study was the anti-depressant, bupropion. The subject population consisted of HIV negative men who have sex with men (MSM) with mild-to-moderate depression.
Interventions
- DRUG Placebo
- DRUG Bupropion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2002-09 |
| Est. Completion | 2004-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00285584
The ClinicalTrials.gov registry entry for NCT00285584 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00285584 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00285584 about?
NCT00285584 is a clinical study titled "Bupropion For Reducing High-Risk Behaviors in Depressed Men Who Have Sex With Men (MSM)". The primary purpose of this study was to test the whether high-risk, HIV-seronegative persons with mild-to-moderate depression would be more likely to adopt protective behavior change when provided with pharmacotherapy for their depression than when treated with placebo. High-risk behaviors include ...
What is the current status of trial NCT00285584?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2002-09. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00285584?
The interventions under investigation include: Placebo (DRUG), Bupropion (DRUG).
Who is sponsoring clinical trial NCT00285584?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.